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Abstract
Background: Despite being in clinical remission, many people with inflammatory bowel disease (IBD) live with
fatigue, chronic abdominal pain and bowel urgency or incontinence that limit their quality of life. We aim to test
the effectiveness of an online self-management programme (BOOST), developed using cognitive behavioural
principles and a theoretically informed logic model, and delivered with facilitator support.
Primary research question: In people with IBD who report symptoms of fatigue, pain or urgency and express a
desire for intervention, does a facilitator-supported tailored (to patient needs) online self-management programme
for fatigue, pain and faecal urgency/incontinence improve IBD-related quality of life (measured using the UK-IBDQ)
and global rating of symptom relief (0–10 scale) compared with care as usual?
Methods: A pragmatic two-arm, parallel group randomised controlled trial (RCT), of a 12-session facilitator-supported
online cognitive behavioural self-management programme versus care as usual to manage symptoms of fatigue, pain
and faecal urgency/incontinence in IBD. Patients will be recruited through a previous large-scale survey of unselected
people with inflammatory bowel disease. The UK Inflammatory Bowel Disease Questionnaire and global rating of
symptom relief at 6 months are the co-primary outcomes, with multiple secondary outcomes measured also at 6 and
12months post randomisation to assess maintenance. The RCT has an embedded pilot study, health economics
evaluation and process evaluation.
We will randomise 680 patients, 340 in each group. Demographic characteristics and outcome measures will be
presented for both study groups at baseline. The UK-IBDQ and global rating of symptom relief at 6 and 12months
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post randomisation will be compared between the study groups.
Discussion: The BOOST online self-management programme for people with IBD-related symptoms of fatigue, pain
and urgency has been designed to be easily scalable and implemented. If it is shown to improve patients’ quality of
life, this trial will enable clinicians and patients to make informed management decisions. This is the first trial, to our
knowledge, focused on multiple symptoms prioritised by both people with IBD and health professionals.
Trial registration: ISRCTN71618461. Registered on 9 September 2019.
Keywords: RCT, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Fatigue, Pain, Faecal incontinence,
Online self-management
Background
Inflammatory bowel disease (IBD) causes unpredictable
bouts of gut inflammation, with acute illness, diarrhoea,
and pain. In remission, many people with IBD live with
fatigue, chronic abdominal pain and bowel urgency/in-
continence [1]. There is no current cure for IBD, which
usually starts in childhood or as a young adult. Most
previous IBD research has focused on controlling in-
flammation. However, many people report continuing
IBD-related fatigue (41%), abdominal pain (62%) and dif-
ficulty with continence (up to 75%) even when IBD is in
remission [1–3]. Although patients in clinical remission
may still have a burden of inflammation detected endo-
scopically or histologically, even patients with clinical
and endoscopic/ histologic healing often continue to ex-
perience these symptoms. These symptoms limit peo-
ples’ quality of life and ability to work and socialise.
Patients feel that these symptoms are not taken seriously
by health professionals and report that little help is given
[2, 4, 5]. The James Lind Alliance IBD research priority-
setting consensus put fatigue, pain and incontinence
amongst the top 10 issues that IBD patients and clini-
cians want to be addressed by research [6].
The IBD-BOOST programme of research
The current Randomised Controlled Trial (RCT) is stage
4 of IBD-BOOST, a UK National Institute for Health Re-
search (NIHR) Programme Grant for Applied Research
(PGfAR) funded programme (grant reference RP-PG-
0216-20001). This programme aims to improve the qual-
ity of life of people with IBD by reducing the burden of
IBD-related fatigue, abdominal pain and urgency/incon-
tinence. Table 1 shows the four stages of the IBD-
BOOST programme including this RCT.
Rationale for the choice of a cognitive
behavioural intervention
Symptoms of fatigue, pain and urgency/incontinence
have a major impact on quality of life of people with
IBD [1–3]. Despite this, there has been remarkably little
research on managing these troublesome IBD symptoms.
Cognitive behavioural (CB) theories of these symptoms
in other conditions suggest that disease factors trigger
symptoms, but an interaction of cognitive, behavioural,
emotional, environmental and physiological factors may
strengthen and/or perpetuate them [7–10]. For instance,
believing that pain and fatigue signal damage to the body
(cognitions), may lead to avoidance of activity (behav-
iour) and distress (emotion). Distress activates the auto-
nomic nervous system (physiology) which may generate
additional symptoms, lead to poor sleep and perpetuate
fatigue and pain. CB-based interventions which aim to
alter these responses have been shown to reduce symp-
tom severity and improve quality of life in other long-
term conditions [11–13]. Online delivery of these inter-
ventions for chronic pain and fatigue appear effective in
other conditions, with evidence of enhanced effects
through the addition of minimal health care professional
support [14–18].
Most studies in other medical conditions have focused
on either fatigue or pain. Having separate CB interven-
tions for each major symptom in IBD would create a
substantive treatment burden. CB therapy (CBT) has
Table 1 The IBD-BOOST programme of studies on fatigue, pain
and urgency in IBD
Stage 1 of the programme involved focus groups and interviews with
people with IBD and IBD nurse specialists. In line with MRC guidance,
these data were used alongside a theory-and person-based approach to
develop a digital cognitive behavioural self-management intervention
(IBD-BOOST). This stage is now completed.
Stage 2 of the programme involves a large cross-sectional survey of
people with IBD to investigate the inter-relationships of IBD-related fa-
tigue, pain and urgency/incontinence symptoms and the proportions
wanting support to manage these symptoms. This stage is in progress
and is not described further here.
Stage 3 of the programme is a non-randomised experimental study to
test the effectiveness of a checklist and algorithm for identifying and
treating medical causes of these IBD-related symptoms. The medical ab-
normalities detected in the study will be treated. This stage is not part
of the current RCT and is not described further here.
Stage 4 (the current study) is an RCT of online self-management for
symptoms of IBD fatigue, pain and urgency/incontinence (IBD-BOOST),
with an embedded pilot study, health economics evaluation and
process evaluation. Potential participants will already have completed
the IBD survey (stage 2). Some of them will also have participated in
stage 3.
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been shown to be an effective treatment for irritable
bowel syndrome (IBS) [12, 19]. As IBS is a multi-
symptom condition, including abdominal pain alongside
bowel disturbance, creating a single intervention to help
manage all three of these IBD symptoms seemed justi-
fied. To test this empirically and in line the MRC frame-
work for developing and testing complex interventions
[20], we conducted a series of modelling studies and sys-
tematic reviews to define the specific cognitive and be-
havioural variables and treatment approaches that would
benefit pain [21, 22], fatigue [2, 23] and urgency [21, 22]
in IBD.
In separate studies, we have shown that severity and
impact of fatigue and pain share several cognitive, emo-
tional and behavioural correlates. For example, both pain
and fatigue were found to correlate with depression,
anxiety, focusing more on symptoms, interpreting these
symptoms as signals of damage to the body and
responding to symptoms with all-or-nothing or avoid-
ance behaviours [22, 23]. All-or-nothing behaviour is
when individuals exert themselves when symptoms are
mild or absent, feel extreme fatigue or pain as a result
and then avoid activity or rest up until symptoms sub-
side again [23]. In IBD fatigue, psychosocial factors ex-
plained 41% of variance after controlling for disease
status. In IBD pain, psychosocial factors explained 9.5%
of variance in IBD pain severity and 24% of variance in
IBD pain interference when controlling for demographic
and clinical variables [22].
Similar processes have been observed in people ex-
periencing bowel urgency, as hypersensitivity to rectal
sensation leads to constant monitoring of rectal con-
tents (hypervigilance) and anxiety in anticipation of
incontinence [24]. Anxiety stimulates gut peristalsis
and triggers a need to rush to the toilet; running
makes incontinence more likely. Amongst people with
IBD-related incontinence, 58% feel that anxiety
worsens incontinence; even those who never experi-
ence incontinence worry about the possibility [3, 5].
The long-term impact of these psychological re-
sponses may perpetuate and maintain low mood and
symptom chronicity, due to the physiological effects
of the stress response, disrupted circadian rhythms,
deconditioning and inflammation via the autonomic
nervous system [10]. The aim of our intervention was
therefore to target these transdiagnostic factors
through evidence-based cognitive behavioural tech-
niques focused on breaking vicious cycles, fostering
self-management and improving quality of life [22].
Our modelling work also identified specific symptom-
related factors which are important to include. For in-
stance, to manage urgency in IBD, behavioural methods
to strengthen the pelvic floor and bowel retraining tech-
niques (such as practicing ‘holding on’) help to re-build
confidence and the ability to defer defecation [25–27].
The intervention therefore needed to target both shared
and symptom-specific cognitive and behavioural factors.
To provide an initial map for the content of the inter-
vention, we drew the evidence base together in a con-
ceptual logic model. We also drew content from
previous evidence-based manuals for treating fatigue and
pain in other conditions [10, 28–30] and a self-
management booklet for incontinence in IBD [31]. De-
tails of this process and the role of patient feedback to
refine the intervention will be reported elsewhere (paper
in development).
Rationale for guided web-based self-management
People with IBD have been found to be willing to engage
with, and complete, online self-management interven-
tions [32]. In a 12-month trial in 333 patients, 79.6%
completed the study and 88% finding this feasible and
preferable to face-to-face care [33]. Some minimal health
professional support has been shown to enhance engage-
ment with self-management in IBD and other chronic
conditions [34]. People with IBD want to take a greater
role in self-management, including information that is
both therapeutic and supportive [35]. Previous studies of
online CBT in IBD have shown significantly improved
quality of life, even when participants were recruited
with no specific symptoms to be addressed [36].
In other chronic illnesses, self-management has been
shown to improve management of cognitive symptoms
and reduce fatigue, distress and social limitations [37].
CB models, theory and principles described above are
ideally suited to self-management interventions, provid-
ing a clear structure to develop theoretical models and
treatment mechanisms related to the outcome of interest
(e.g. quality of life related interference of symptoms). CB
models also map onto specific evidence-based tech-
niques to enhance behavioural and cognitive change
relevant to self-management [38, 39].
Our previous experience of recruiting people with IBD
for interventions [31] and extensive patient engagement
and literature on the popularity of electronic self-
management in IBD determined our choice of online
self-management. Although people want help with
symptoms, they do not want repeated hospital visits and
may decline help offered on that basis. We therefore de-
signed BOOST as an online, tailored CB-based self-
management programme which patients could complete
in their own time at home with some minimal guided
support from an IBD nurse trained in the intervention.
This protocol is reported in line with the SPIRIT
(2013) statement. The SPIRIT Checklist can be found in
Additional file 1.
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Methods: objectives, design and setting
Objectives
The study aims to answer the following research
questions:
 Primary research question:
1. In people who report symptoms (scoring at least
5/10 on one or more symptoms on a 0–10 scale
(where 0 = no problem and 10 = worst possible
problem) and express a desire for intervention,
does a facilitator-supported, tailored (to patient
needs), online self-management programme for
fatigue, pain and faecal urgency/incontinence in
IBD improve IBD-related quality of life and glo-
bal rating of symptom relief 6 months after ran-
domisation, compared with care as usual?
 Secondary research questions:
2. Is there any difference between the groups in
severity of symptoms of fatigue, pain and
urgency/incontinence at 6 and 12months after
randomisation?
3. Is there any difference between the groups in
IBD-related quality of life and global rating of
symptom relief 12 months after randomisation?
4. Does prior medical optimisation of symptoms (in
stage 3 of this programme) moderate the
treatment response (i.e. do those receiving
medical optimisation show greater treatment
gains than those who do not) as measured by the
primary outcomes?
5. Do people with IBD in remission at trial
commencement have a better response to
treatment (primary outcomes) than those with
active disease? (remission defined as faecal
calprotectin within normal range (200 or under)
and /or IBD control score [40] of 13 or over.
6. Do baseline depression, or the presence of
irritable bowel syndrome (Rome IV criteria)
moderate treatment response to intervention
(primary outcome measures)?
7. Do changes in illness perceptions and
behaviours, IBD specific anxiety and self-efficacy,
and depression from baseline to 6 months medi-
ate intervention effects on the primary outcomes
at 12 months?
8. Is a facilitator-supported, tailored, online self-
management programme for fatigue, pain and
faecal urgency/incontinence in IBD cost-
effective?
9. What are patients’ expectations and experiences
of the intervention and what factors may have
influenced the intervention implementation
(qualitative work in process evaluation)?
Hypothesis for the RCT
A facilitator-supported, online, tailored self-management
programme for fatigue, pain and faecal urgency/incon-
tinence in people with IBD will result in better quality of
life compared to care as usual at 6 months after
randomisation.
Design for the main RCT
The design is a pragmatic multi-centre two-arm, parallel
group superiority RCT. We will compare facilitator-
supported online self-management versus care as usual
(CAU) to manage symptoms of fatigue, pain and faecal ur-
gency/incontinence in IBD. There are one baseline assess-
ment and two assessments at 6 and 12months after
randomisation. Primary outcomes are as follows: IBD quality
of life and global rating of symptom relief at 6months. The
CONSORT diagram for the RCT is given in Fig. 1.
Internal pilot study
An internal pilot study will test planned methods and
procedures for the main RCT and identify barriers to
the components working together and potential recruit-
ment issues. We will recruit and randomise the first 100
participants in the RCT, aiming to complete this within
the first 6 months of the RCT recruitment. The methods
planned for the main RCT will be followed. If no sub-
stantive changes are made, these 100 participants will be
included in the main RCT analysis. Note: this pilot has
been a little delayed by the Covid-19 pandemic and will
now cover the first 10 months of the RCT.
Study setting
The study will be conducted at National Health Service
(NHS) hospital sites in England with IBD services and at
King’s College London (KCL). A full list of sites is avail-
able from the Chief Investigator on request.
Methods: participants, interventions and
outcomes
Identifying participants
People with IBD with symptoms of fatigue, pain and/or
urgency will be recruited from people responding to our
earlier IBD-BOOST survey (stage 2 of the programme)
or from people who have completed the survey plus
medical symptom optimisation study (stage 3 of the
programme), who request further intervention for these
symptoms and who meet our eligibility criteria (below).
The survey was sent by post or an electronic link in an
email to unselected patients with IBD by IBD clinic hos-
pital sites, the UK national IBD BioResource or the char-
ity Crohn’s & Colitis UK. The completed surveys were
returned by post or electronically.
The central IBD-BOOST research team will screen the
IBD Survey (stage 2) responses and the follow-up
Norton et al. Trials          (2021) 22:516 Page 4 of 18
questionnaires of participants in the IBD-BOOST Op-
timise study (stage 3) who have consented to be con-
tacted for further research. Sufficient English and
capacity for consent will be presumed from the previ-
ous response to the survey. A link to the online con-
sent form for those who wish to participate in the
RCT will be embedded in an email from a member
of the central research team. If the online database is
not available, paper copies of the Participant Informa-
tion Leaflet and consent form will be sent.
Eligibility criteria
Inclusion criteria
 Diagnosis of IBD (self-reported as having been
medically diagnosed with IBD including patients
with an ileo-anal pouch or stoma)
 18 years old or over
 Living in England, Scotland or Wales
 Have participated in stage 2 of the programme
(IBD-BOOST survey) and have self-scored one or
more symptoms of fatigue, pain or urgency/incon-
tinence as having an impact on their quality of life
of 5 or more on a 0–10 scale when completing stage
2 (IBD-BOOST survey) or stage 3 (medical symp-
tom optimisation) (whichever is the more recent)
 No ‘red flags’—see below
 Access to the online intervention via a computer or
mobile device
Exclusion criteria
 One or more ‘red flags’ identified on pre-
randomisation screening (such as new bleeding,
rapid weight loss or vomiting that has not been pre-
viously reported to a health care practitioner), self-
reported on a screening checklist. If ineligible be-
cause of a red flag, a participant may be re-assessed
if they contact the research team and report that the
information they originally provided has changed
such as the symptom has been adequately
Fig. 1 Consort diagram for a randomised control trial of supported self-management for symptoms of fatigue, pain and urgency/incontinence in
people with inflammatory bowel disease
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investigated or managed, in which case the partici-
pant can be included.
 Inability to give informed consent (for example, due
to reduced mental capacity)
 Insufficient command of English to understand
study documents and procedures
Screening for ‘red flags’ and other risks
After participants consent, they will self-complete an on-
line or paper copy checklist to check eligibility criteria
above. Following consent, we will screen patients for
‘red flags’. These are potentially serious issues identified
by our clinical co-investigators that may be undetected
underlying causes of symptoms. If a participant’s re-
sponses indicate a potential red flag, the participant will
be advised to seek a consultation with their health care
team and only recruited to the trial once the symptoms
have been adequately investigated.
We will also send consenting participants who have
not already taken part in IBD-BOOST Optimise (stage 3
of the programme, who will have already done this) a kit
for testing the faecal calprotectin level (see below and
Additional file 5), but non-response to this test will
NOT delay randomisation.
Additionally, item 9 (suicidal ideation) of the PHQ-9
in the baseline questionnaire (see below) will be
reviewed to assess for risk of harm/suicidal ideation. If
the participant has scored 2 or 3 (indicating frequent
thoughts around suicidal ideation) then a risk assess-
ment will be carried out by a psychologist by telephone.
Participants assessed as low or medium risk will be able
to continue into the trial, reminded of resources to ac-
cess for further support and provided with an optional
template letter to notify their GP. Appropriate urgent
action will be taken for patients assessed as high risk
and these individuals will not proceed into the trial.
Study interventions
BOOST is a web-based programme for self-management
of pain, fatigue and urgency/incontinence symptoms in
IBD based on the principles of CBT. ‘BOOST’ was ini-
tially mapped out based on the theoretical models de-
scribed above and then developed with extensive patient
and IBD specialist nurse input. BOOST has undergone
extensive user feasibility testing prior to the pilot study,
as recommended by the Medical Research Council when
developing complex interventions [20].
BOOST includes 12 online sessions which can be
viewed on computer, smart phone or tablet (however,
participants are advised that computer or tablet is likely
to give a better view of the programme). The content
has been developed to be interactive and tailored to pa-
tients’ needs. A number of logic pathways have been
programmed into the programme alongside self-
assessments, so the computer only provides content and
tasks relevant to issues identified by the participant.
Sessions 1–7 are core sessions to be completed by all
participants experiencing fatigue, pain and faecal ur-
gency/incontinence. Based on a Cognitive Behavioural
model of IBD symptoms, the core sessions cover topics
around understanding IBD symptoms, balancing activity
and exercise, sleep hygiene, changing negative thoughts,
coping with stress and emotions, and making the most
of social support. These core sessions have associated
tasks for participants to complete in between sessions in
their day-to day-life, such as working toward completing
goals or keeping a sleep diary. Sessions 8–11 are
symptom-specific sessions to be completed by partici-
pants experiencing or with a specific interest in fatigue,
pain and faecal urgency/incontinence, respectively. Some
of the content of the website was adapted from previous
manuals using a similar approach for managing specific
symptoms in IBD or with different illness populations
[31, 41–46]. Table 2 provides a summary of each session
for all BOOST sessions. The symptom-specific sessions
provide participants with more in-depth psychoeduca-
tion on the interaction between medical and psycho-
social factors contributing to the severity and impact of
the specific symptom, together with practical tips and
ongoing exercises on how to better manage them.
Participants will be able to log into BOOST via a com-
puter, tablet or smart phone, according to their prefer-
ence, and advised to complete approximately one
session per week. Each session takes 30–60min to
complete. Participants will be able to complete the ses-
sions at a time and place that is convenient to them and
to pace themselves in a way that suits them and their
lifestyle.
Facilitator support
During the intervention, the participants will be sup-
ported by an assigned healthcare professional, who will
act as their facilitator. Facilitators will be recruited (and
trained) from our 15–20 sites, aiming for at least 2 per
site, enhancing generalisability. Facilitators will predom-
inantly include IBD nurses and a small number of aca-
demic psychologists within the research team in
instances where nurses are not available, for instance
supporting participants recruited through non-hospital
sites.
The programme suggests one 30-min phone call after
participants have completed session 1, and then online
messaging from the participant to the facilitator as the
participant wishes thereafter. During the phone call, the
facilitator will review the participant’s personal vicious
cycle completed in session 1, guide the participant’s un-
derstanding of factors contributing to symptoms from a
cognitive behavioural model and review the participant’s
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programme aims. Each facilitator will use a telephone
checklist prompt sheet to guide the telephone call. At
the end of each online session, the participant is
prompted to consider if they want to send a message.
The facilitator can reply to online messaging within the
intervention platform. The facilitator will have access to
information on how participants are using the interven-
tion (sessions and task completed) and will monitor and
help to promote participants’ engagement with the inter-
vention, together with supporting participants work to-
ward achievement of their intervention goals. Facilitators
will be encouraged to log in weekly to check their partic-
ipant’s completion of sessions/tasks and send any neces-
sary messages to promote engagement, as well as reply
to messages received.
 Group 1 (intervention): Access to care as usual plus
the online tailored BOOST self-management
programme for 6 months, plus one individual tele-
phone or Skype support session (for up to 30 min,
training and a paper copy of the content will be pro-
vided for the facilitator), plus access to online
messaging with their facilitator via the BOOST plat-
form for the first 3 months after recruitment.
Participants will log in to the online programme
(unique login), undertake symptom self-assessment, pri-
oritise what symptom they want to work on, with sign-
posting to relevant sections depending on symptoms
and response to online questions. (Example: link to a
section on improving sleep patterns for those with fa-
tigue who nap a lot in the day or with a problem getting
to sleep at night).
 Group 2 (control): Care as usual (CAU).
All participants will have access to all usual IBD care,
including monitoring with clinic visits and/or via the
local IBD helpline (this will constitute care as usual for
group 2).
Participants in group 1 with an active IBD flare
during intervention will not be expected to discon-
tinue the intervention and will have continued access
to the online programme. All randomised participants,
regardless of whether they have reported a disease
Table 2 Intervention sessions
Session 1. Understanding your IBD symptoms Factors that can contribute to fatigue, pain and urgency in IBD. Identifying specific factors and
developing a personal vicious cycle of symptoms. Use of self-monitoring not symptom focusing.
Setting aims for the programme.
Task: Symptom severity and stress level diary.
Session 2. Balancing your activity, eating and
exercise
Importance of activity and exercise. How fear leads to avoidance. Eating patterns. Setting goals for
activity and exercise.
Task: Reviewing and working toward goals for activity + sleep diary.
Session 3. Improving your sleep Why is sleep important? Sleep patterns & habits. Improving sleep.
Setting goals for sleep.
Task: Reviewing and working toward goals for sleeping patterns and habits.
Session 4a. Changing your thoughts: Part 1 Why are thoughts important? Identifying unhelpful thinking.
Task: Thought record.
Session 4b. Changing your thoughts: Part 2 Developing alternative thoughts.
Task: Alternative thought record.
Session 5. Managing stress and coping with
emotions
The effects of stress and finding ways to manage it. The role of emotions and determining how
best to take care of oneself. Setting goals for managing stress and emotions.
Task: Reviewing and working toward goals for stress management + stress diary.
Session 6. Making the most of your social
support and communication
Types of social support. Communication and disclosure. Setting goals for social support.
Task: Reviewing and working toward goals for social support.
Session 7. Managing and understanding
fatigue in IBD
Types of fatigue. Factors related to IBD fatigue. Exploring a vicious cycle of IBD fatigue; the role of
thoughts, emotions and behaviours.
Session 8. Managing and understanding pain
in IBD
Difference between acute and chronic pain in IBD. Factors related to IBD pain. Exploring a vicious
cycle of IBD pain; the role of thoughts, emotions and behaviours. Common questions around pain
in IBD.
Session 9. Managing urgency and leakage Bowel functioning and bowel control difficulties. Stress and anxiety in urgency. Exercises to help
reduce accidents. Practical bowel management tips. Using social networks to help manage
urgency.
Session 10. The role of acceptance and self-
compassion in pain
What is acceptance and how can it help? The role of resilience. Practical exercises.
Session 11. Summary and maintaining
improvement
Reviewing programme aims. Preparing for the future. Sustaining and building upon improvements.
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flare or not, will be sent the questionnaires to capture
outcome measures at 6 and 12 months after
randomisation.
At 12 months, participants allocated to CAU will be
offered access to the online intervention (but no facilita-
tor support). Uptake within 6 months will be reported.
For use of primary and secondary healthcare, other
health care resources and medication use will be col-
lected using the baseline, 6- and 12-month follow-up
questionnaires (see Economic Evaluation section below).
We have worked with our patient panel to devise
strategies to optimise engagement with the online inter-
vention and retention of our sample, such as persona-
lised text or email reminders.
Facilitator training and intervention fidelity
There will be specific training for facilitators on deliver-
ing the intervention and the principles of CBT via a
manual (which contains the full text of the online inter-
vention for reference) and a 1-day intensive course deliv-
ered by expert psychologists in the intervention
development team. The training will introduce facilita-
tors to the principles of a cognitive behavioural ap-
proach, provide opportunity to observe and practice
telephone call role plays and review example models of
vicious cycles of symptoms which participants will con-
struct during session 1. The training will also cover
responding to online messaging, and what to do in cer-
tain situations (e.g. the participant not engaging with the
programme, getting stuck or frequent or persistent use
of the messaging service). Adverse events will be dis-
cussed and the manual contains standard operating pro-
cedures (SOPs) for actions to be taken in certain
scenarios, such as the participant appearing very de-
pressed or suicidal.
Facilitators will receive further training and supervi-
sion during the site initiation visit from the intervention
development/trial team. Prior to starting the trial, facili-
tators will also receive one-to-one supervision on a
‘practice patient’ (a person with IBD from our Patient
and Public Involvement panel) over a 2-week period. A
practice telephone session between facilitator and pa-
tient will be audio-recorded for training purposes, where
facilitators will use the telephone checklist prompt sheet
to guide the call. Facilitators will receive feedback from a
member of the intervention development team on the
telephone conversation and online messaging responses
with the practice patient.
Online messaging contacts will be recorded and ana-
lysed in the process evaluation (below). Facilitators will
receive monthly supervision (or on request of the facili-
tator) with a trained member of the research team to en-
sure fidelity and provide support for any difficult issues
that may arise. Supervision will include reviewing online
messaging and tasks. Participants are told when they
commence the online programme that their facilitator
and the supervisor will be able to see their messages and
tasks. Facilitators will complete the telephone checklist
prompt sheet for each participant and provide these to
the research team, and receive supervision on a trial pa-
tient telephone call, upon the patient’s permission for a
psychologist to listen (but not audio record). At the end
of the trial, a randomly selected sample of online mes-
sages will be rated for fidelity by an independent rater
(see process evaluation below).
Discontinuation criteria
We do not have any criteria for discontinuing a
participant.
Outcomes
Trial outcome measures have been selected following
focus group opinions and refined with our patient panel.
Primary outcome measures
UK Inflammatory Bowel Disease Questionnaire (UK-
IBDQ) [47] and global rating of symptom relief at 6
months after randomisation.
Other measures (at baseline, and as secondary outcomes
at 6 and 12months after randomisation)
 UK-IBDQ [47] at 12 months
 Rating of satisfaction with results of IBD-BOOST
programme (simple 0–100 visual analogue scale) at
6 and 12 months only
 Global rating of symptom relief at 12 months
 Numerical (0–10) pain rating scale
 Vaizey (faecal) incontinence score [48], reflecting
patients’ perceptions of severity [49]
 IBD-Fatigue score [50, 51]
 IBD-Control score; 8-item self-reported score to
measure disease control from the patient’s perspec-
tive [40]
 EQ-5D-5L [52] general health-related quality of life
at baseline and 6 and 12 months after randomisation
Health economic measure (at baseline, and 6 and 12
months after randomisation)
 IBD Resource Use Questionnaire to determine
health care and other resource use and costs due to
IBD, including visits or phone calls to primary and
secondary healthcare services, medication use and
personal expenses.
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Moderators and mediators
These include measures which may either moderate or
mediate the treatment response. These data are important
in terms of variables which may help to explain response,
to be used as part of process evaluation (see below): (at
baseline, 6 and 12months after randomisation):
 Symptoms which determine a co-diagnosis of irrit-
able bowel syndrome (IBS) and IBD: Rome IV cri-
teria for IBS
 Medications for depression, pain and diarrhoea
 Measures of change in general mood: depression as
measured by the Patient Health Questionnaire (PHQ-
9) [53]. This measure includes a question (item 9) that
may indicate suicidal thoughts. The action to be taken
if suicidal thoughts are indicated is described in
‘Assessment and management of risk’ below.
 To measure self-efficacy: Self-efficacy for managing
chronic disease 6-item scale [54]
 To measure IBD/illness specific cognitions: Brief
Illness Perceptions Questionnaire (BIPQ) [55]
(minus the open ended causal items). Items are
prefaced in relation to beliefs about IBD symptoms
rather than IBD generally.
 Medications for depression, pain, diarrhoea
 To measure IBD/illness specific affect: Visceral
Sensitivity Index (VSI): gastrointestinal symptom-
specific anxiety [56]
 To measure behaviour: All-or-nothing and avoid-
ance/resting subscales from the Cognitive and
Behavioural Responses to Symptoms Questionnaire
(CBRQ)
Note: these outcome sets are questionnaires validated
for self-completion and will be compiled into a single
online questionnaire (available from the Chief Investiga-
tor). We recognise the potential burden on participants
of these multiple outcome measures (just under 150
questions). However, as we are assessing multiple symp-
toms and are keen to include potentially explanatory
variables, we feel that these are necessary. We have
worked with our PPI representatives on optimising for-
mat for outcome measures in a user-friendly online
interface.
Participant timeline
This is shown in Table 3. There are no face-to-face
visits; all study procedures are completed remotely by
post, telephone or online messages.
Sample size
Our primary outcome is the UK-IBDQ, range 0 to 120
where low values indicate poor quality of life. Using sev-
eral published studies [47, 57, 58], we estimate the stand-
ard deviation of the change in score to be between 20 and
30. This would mean an effect size of 0.3 would equate to
a difference of between 6 and 9 points on the scale. In the
validation study [47], the difference in score between those
with mild disease and disease in remission was 12 points
and the effect of relapse was 10 points.
Table 3 IBD-BOOST RCT screening and data collection schedule (SPIRIT figure)
Pre-consent Pre-baseline Baseline 6 months 12months Ongoing or during treatment
Screen for eligibility X
Study within a trial (SWAT) randomisation X
Invite reply X
Consent form X
Red flags assessment X
Adverse event form X
Drop-out event form X
Faecal calprotectin test X
Baseline case report form X
Follow-up case report form X X
Participant qualitative interviews X X
Clinician qualitative interviews X X
Randomisation X
Nurse support X
Intervention website user query X
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An effect size of 0.3 was observed in a small study of
dietary advice in patients with ulcerative colitis [57].
We will randomise 680 patients, 340 in each group.
Assuming a 20% loss to follow-up, there will be 270 in
each group in the analysis. Assuming there are 30 facili-
tators, they will each support ~ 11 patients on average of
whom ~ 9 will contribute to the analysis. If the ICC for
clustering between facilitator is 0.04, the design effect
will be 1 + 0.04 × 8 = 1.32 and the effective sample size
in the intervention arm is 270/1.32 = 204. 270 in the
control and 204 in the intervention arm would allow an
effect size of 0.3 to be detected with 90% power.
A 20% drop-out assumption is based on drop-out rates
from previous studies of self-management: 19.2% of 682
participants in IBD disease self-management (not online)
[59]; 20.4% of 333 participants for online self-management
of ulcerative colitis disease flares [33]; 18% control and
16% intervention of 1140 participants randomised for
chronic disease self-management in other diseases [37].
Recruitment
The previous stage of our programme involves a large-
scale survey about symptoms to people with IBD. We
will continue sending out batches of this survey until we
achieve adequate recruitment for the RCT. Respondents
to this separate survey who are apparently eligible to
participate in the RCT will be sent an invitation, a par-
ticipant information sheet, a consent form and a further
pre-randomisation eligibility checklist for ‘red flags’ (see
eligibility criteria above) electronically or by post. Once
a patient has consented and is eligible, a baseline ques-
tionnaire is sent.
Methods: assignment of interventions
Randomisation procedures
Participants who consent, are eligible and return the
baseline questionnaire (which is different form the sur-
vey they will have already completed) will be randomised
by the central research team using an online randomisa-
tion system developed for the study by the PCTU. Allo-
cation will, therefore, be concealed until consent and
baseline measurements have been completed. It is not
possible to blind participants or facilitators once ran-
domisation has occurred, due to the nature of the
intervention.
The central team will inform the participant which
group they are in and inform the clinical sites of partici-
pants in group 1 who will receive local facilitator sup-
port (phone call and online messaging). The local
facilitator will be given the participant’s details and ac-
cess to their online tasks.
Stratified central web-based randomisation to 2
groups. Stratified by:
 Diagnosis (Crohn’s disease vs. any other type of IBD,
including ulcerative colitis and IBD-unclassified)
 Whether or not participated in the stage 3 study in
this programme (medical symptom optimisation)
Random block sizes of 4 and 6 will be used. Block
sizes will not be disclosed to ensure allocation
concealment.
Blinding procedures
Faecal calprotectin level will be entered into the database
by a person blinded to group allocation when the result
has been returned from the laboratory and the partici-
pant informed of the result. Blinding of participants or
facilitators is impossible. Data cleaning for the outcome
measures will be by a statistician blinded to group allo-
cation. Blinding beyond this will be impossible as data is
clustered by the facilitator in the intervention arm only.
Methods: data collection, management and
analysis
Data collection methods
Outcome measures will be collected by either direct par-
ticipant input into a secure online study-developed data-
base managed by the QMUL Pragmatic Clinical Trials
Unit (PCTU) or via paper copies sent by central research
team at KCL. Paper copies received in the post will be
inputted manually into the database by the research
team at KCL. The questionnaires will not be available in
any languages other than English. Each clinic or site will
complete a study log for all their participants who have
been contacted for the study. Two email or text re-
minders will be sent to non-responders. If there is still
no response, an attempt will be made to collect the pri-
mary outcome measure by telephone.
Window for return of outcome measures is as follows:
up to 8 weeks (with reminders) at the 6-month follow-
up and up to 4 weeks (with reminders) at the 12-month
follow-up (with up to 2 text or email reminders). If pri-
mary outcome measure is not returned by 8 weeks after
the 6-month time point, an attempt will be made to have
this (the IBDQ and global rating of symptom relief only)
completed over the phone by a member of the central
trial team reading out the questions and recording the
responses.
Baseline demographic details (age, gender, type of
IBD) and ROME IV criteria for irritable bowel syndrome
[60] will be collected.
We will adopt evidence-based methods to minimise
loss to follow-up which have been identified in a system-
atic review [61]. These include providing incentives to
participants, contacting respondents prior to sending the
follow-up questionnaires and using phone, text and
email to contact participants. To optimise our response
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rates, we will provide an unconditional inconvenience
payment of £5 at 6 months and 12months by post with
a letter at the same time as we send out the follow-up
questionnaire electronically or by post.
Data management
Data will be stored on a secure database. Participants
will complete the outcome measures via an online link
and will input their data directly into the database or
complete paper copies and send via a provided stamped
addressed envelope. Further details are available from
the Chief Investigator. All interviews will be digitally re-
corded, anonymised, professionally transcribed verbatim




Baseline demographics, type of IBD classification, Rome
IV IBS criteria and baseline values of outcome variables
will be presented for both study arms using descriptive
statistics only.
The UK-IBDQ and global rating of symptom relief will
be compared between the two study arms at 6 and 12
months after randomisation (analysis conducted after 12-
month data collection point). The following covariates will
be included in the model: baseline value of outcome mea-
sures, stratification factors, fatigue, pain and incontinence
at baseline, age and gender. Facilitators will be added as a
random effect in the intervention arm only.
Secondary outcomes will be analysed in the same way with
inclusion of baseline value of respective outcome. Outcomes
and covariates may change in the light of new information
but will be agreed prior to unblinding of the data.
Pre-specified subgroup analyses to investigate sub-
groups who might respond better to treatment will be
conducted as part of the process evaluation (see below).
A sensitivity analysis using imputation methods to
allow for missing data and reasonable assumptions for
those lost to follow-up will be carried out.
A detailed statistical analysis plan will be completed
and signed off by the Programme Steering Group prior
to unblinding of data.
Economic evaluation methods
An economic evaluation using recommended methods
[62] will be undertaken from the National Health Service
/Personal Social Services and patients’ perspectives to
evaluate the cost-effectiveness of the intervention at 12
months. The cost of the intervention, including facilita-
tor’s contacts with each patient, website hosting and
maintenance and facilitators’ training (venue, trainers’
and facilitators’ time, travel and subsistence,
administrative support and materials) and supervision,
will be evaluated.
Data on the use of health, social care and other ser-
vices will be collected from all study participants using a
study-specific IBD Resource Use questionnaire, devel-
oped within this Programme Grant, asking about con-
tacts with primary and secondary care, investigations,
medications, hospitalisations, employment and out-of-
pocket expenses.
Unit costs will be sourced from national sources (e.g.
Personal Social Services Research Unit: Unit Costs of
Health and Social Care; Department of Health: NHS ref-
erence costs; British National Formulary; NHS Improve-
ment: National tariff payment system) and will be
applied to categories of resources used to estimate indi-
vidual participant total costs. Health-related quality of
life data will be collected using the EuroQoL EQ-5D-5L
questionnaire.
We will follow the intention-to-treat principle, and
missing data will be handled using multiple imputation
approach. We will calculate quality-adjusted life years
(QALYs) and total costs for each participant in the trial
during the 12months follow-up. We will evaluate the in-
cremental QALYs and costs with allocation to the
BOOST intervention and the intervention’s cost-
effectiveness at 12 months follow-up. The costs and EQ-
5D-5L utilities will be compared between the two study
arms at 6 and 12 months after randomisation, with ad-
justments made for baseline values of outcome measures
(costs in previous 3 months and EQ-5D-5L at baseline),
stratification factors, fatigue, pain and urgency/incontin-
ence at baseline, age and gender. Facilitators will be
added as a random effect in the intervention arm only.
An incremental cost-effectiveness ratio (ICER) will
be estimated as the additional cost per an additional
QALY gained. Uncertainty around the ICER point es-
timate will be assessed [63]. The probability of the
online IBD self-management intervention being cost-
effective compared to usual care will be estimated at
the NICE threshold values of £20,000 to £30,000 per
QALY gained. One-way sensitivity analyses will be
conducted to explore the uncertainty associated with
the cost of the intervention and use of healthcare
services.
A health economics analysis plan, specifying the health
economics analyses in detail, will be finalised and signed
off prior to unblinding of data.
Methods: process evaluation
Research question
What factors (promoters and blockers, individual and
organisational) impact on the completion and effect of
the intervention?
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A mixed methods process evaluation of the RCT will
be conducted based on the MRC guidance [64]. The de-
sign of the process evaluation is based upon the logic
model and consequent discussion within the study team,
so that the process evaluation can explore the areas of
greatest uncertainty.
Aims
To investigate the processes through which the interven-
tion is delivered, and what is actually delivered in prac-
tice, to aid the interpretation of the results of the main
trial and to inform future rollout and implementation of
the intervention, if successful.
Objectives of the process evaluation
 Determine expectations at baseline through
interviews
 Determine if the intervention was delivered as
planned (intervention fidelity)
 Explore participant responses to the intervention
both quantitatively (through routinely collected
study process data) and qualitatively (through
interviews)
 Explore participants’ responses to being in the
control arm of the study through interviews
 Understand IBD nurses’ views of the intervention
and its integration and usability in everyday NHS
care through interviews
 Consider any potential contextual influences on the
intervention implementation and outcomes.
Based on the logic model developed for the inter-
vention, which provides a detailed description of the
intervention and its causal assumptions, we will seek
to monitor intervention fidelity and provide insights
into how the intervention did or did not work in
practice, any unintended consequences, as well as
providing information to aid future implementation
and dissemination. A list of key assumptions and un-
certainties has been developed by the intervention de-
velopment team. These will be explored and tested in
this process evaluation.
The process evaluation will run concurrently with the
RCT in a largely ‘passive’ model [64]. However, this pas-
sive model will not be operational during our internal
pilot study and the teams will work closely together dur-
ing the pilot to address any issues raised.
Adherence
Fidelity to the protocol
Proportion of people randomised to the intervention
who clicked on the link to the online intervention and
commenced the intervention and completed a minimum
of four online sessions will be considered to have ad-
hered to the intervention. We will also assess the date
the baseline CRF is completed, date ‘red flags’ were com-
pleted and the date randomised to check study processes
worked as intended.
Quantitative
 Monitoring online log-ins (number and spacing/tim-
ing of log-ins and time spent on each section and in
total): automatically collected by the programme
software, enabling us to see how participants inter-
act with the intervention.
 A record of number and time of facilitator telephone
support sessions or emails.
 Evaluation of moderators and mediators of
treatment effect section, below gives details of
quantitative analysis of possible moderators and
mediators of response to intervention.
Qualitative
 Fidelity to the intended facilitator support: a sub-set
of facilitators’ messages will be analysed and com-
pared with instructions in the training manual for fi-
delity to the intended facilitator support. All
facilitator interactions online with participants will
be captured and randomly selected interactions
(messaging) will be stripped of all personal identify-
ing data and subjected to content analysis [65], to
enable assessment of intervention fidelity (as defined
by the training day and intervention manual).
 Face-to-face, telephone or Skype interviews with a
purposive sample of up to 30 recruits (or until
apparent data saturation) before and after the
intervention (attempting to recruit the same people
before they know their group allocation and then
the same people 6 months later; if it is not possible
to recruit people for a second interview at 6 months
(or when they drop out if this is sooner), these
participants will be replaced by another participant
who was allocated to the same group with broadly
the same characteristics). Interviews will be
completed at different times after recruitment, to
understand expectations and experiences of the
intervention, its acceptability and which aspects they
felt were most or least helpful (informing
adjustment to the intervention before future
rollout), and for their opinions on changes in their
cognitions and behaviours. We will also interview at
least two thirds of the facilitators who are IBD nurse
specialists (approx. 20: or until apparent data
saturation) to understand their views on supporting
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the online intervention and fit with their existing
workload.
Participants who have indicated on the trial consent
form that they are happy to be approached about inter-
views will be purposively selected and consented for in-
terviews. Facilitators indicating willingness will be
interviewed. The topic guides for interviews have been
developed with our PPI panel. Data will be analysed it-
eratively and as the interviews progress the topic guide
will be adapted, based on themes which emerge from
earlier interviews, to enable exploration of issues which
appear relevant in later interviews.
The interview sample will be purposively selected to
include both sexes, a range of ages, both IBD diagnoses
and those who completed or did not complete (the
intervention), or were in the CAU group to better
understand patient perspectives on the intervention, ex-
periences of being in a wait list control and whether this
altered behaviours and cognitions around symptoms,
whether non-completion was due to the design and de-
mands of the intervention, or due to other factors.as well
as any unanticipated pathways and consequences. For
analysis, interpretive data analysis will be informed by
the Analytical Hierarchy Framework (AHF) [65], guiding
methods for handling, analysing and generating findings
from qualitative data.
We will train patient volunteers to co-analyse anon-
ymised qualitative data (as we have done successfully in
other studies [4, 66–69]), and help us interpret and
present our findings widely to patient and media audi-
ences. NVivo software will be used to manage data and
enable sorting, labelling and retrieval of data segments
prior to the human endeavour of interpretation and rep-
resentation of findings.
The process evaluation team will work to integrate
these sources of qualitative and quantitative data into a
coherent report which seeks to illuminate the results of
the RCT. There will also be a mediation analysis (see
above).
Evaluation of moderators and mediators of treatment
effects
The purpose of this additional quantitative process ana-
lysis is twofold:
1. To explore moderators of intervention effect
This will allow us to assess if there are any key sub-
group effects and if the intervention should in future
target specific groups of patients. For instance, if depres-
sion and disease activity moderate treatment effects, it
may be best to focus the intervention on patients in re-
mission and provide alternate treatment to people with
depression. If medical treatment optimisation moderates
outcome, then again this confirms best practice would
be to provide optimised medical treatment before the
intervention. Alternately, if there are no significant mod-
erators of effects, the intervention may be generalisable
to the broader IBD population.
Subgroup analyses to be investigated are those who
underwent Optimise (stage 3); IBD in remission (see def-
inition above); baseline measure of anxiety and depres-
sion (PHQ-9 and VSI); and ROME IV criteria for IBD
met at baseline or not. These will be investigated by add-
ing interactions terms to the analysis models used for
the primary outcomes (UK- IBDQ and global symptom
relief).
2. To explore mediators of change
Mediation analysis using structural equation models
allows us to explore if a treatment effect occurs through
hypothesised treatment mechanisms. We have based our
choice of mediator measures on our cognitive behav-
ioural model underpinning the intervention and de-
scribed in our logic model (available on request form the
lead author). Putative mediators have been mapped onto
the key intervention components, i.e. the factors the
intervention attempts to target to bring about improve-
ments in symptom and quality of life. These include the
following: the Visceral Sensitivity Index (VSI [56] and
PHQ-9 [53] for symptoms of anxiety and depression;
Self-efficacy for managing chronic disease 6-item scale
[54]; Brief Illness Perception questionnaire [55]; All-or-
nothing and avoidance/resting subscales from the Cogni-
tive and Behavioural Responses to Symptoms question-
naire (CBRQ); IBD-Control [40]; faecal calprotectin [70];
satisfaction with outcome.
We are looking at whether proximal change in the me-
diators at 6 months predicts improvement in the out-
comes at 12 months.
Methods: monitoring
Data monitoring
A study monitoring and auditing plan will be produced.
The risk assessment for the trial will be under continual
review to assess relevance and applicability and to iden-
tify any actions that may be required. The study may be
subject to inspection and audit by the sponsor and other
regulatory bodies to ensure protocol compliance and ad-
herence to GCP and the UK Policy Framework for
Health & Social Care Research 2017. Protocol deviations,
non-compliances or breaches from the approved proto-
col must be reported to the Sponsor R&D Office and
PCTU within 24 h of becoming aware of the event.
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Harms
Assessment and management of risk
This is a low-risk study (as assessed by PCTU), although
there is potential for participants to become distressed
when thinking about their symptoms. The intervention
site will include a link / website address to CCUK who
provide support via their helpline, and contact details
are included in the Participant Information Leaflet. The
outcome measures include questions on anxiety and de-
pression and the PHQ-9. The central research team will
monitor responses to suicidal thoughts and contact the
patient and undertake a risk assessment if necessary. At
the end of the questionnaire, there are helplines listed
that can offer support.
Risks/benefits
Stopping the trial
There is no Data Monitoring Committee for this low-
risk study. The trial may be prematurely discontinued by
the Sponsor or Chief Investigator on the basis of new
safety information or for other reasons given by the
Programme Steering Committee or REC concerned.
There will be no formal stopping rules based on the
intervention outcomes. In the unlikely event that the
study is prematurely discontinued, active participants
will be informed and no further participant data will be
collected.
Adverse events (AEs)
Adverse events will be assessed using the follow-up
questionnaire at the 6- and 12-month follow-up and
may also be recorded by facilitators through communi-
cation with participants in the intervention arm. We will
also attempt to capture any unforeseen consequences in
the qualitative interviews.
Expected events
Expected AEs include planned/elective hospitalisations,
or unplanned but expected hospitalisation due to flare-
up of IBD: these are expected during the course of the
trial and will not be collected or reported as serious AEs
(SAEs).
After a SAE, a decision will be made by the trial team,
after advice from the relevant authorities and the partici-
pant’s IBD team, as to whether the participant should be
withdrawn from either their randomised treatment or
from the trial. However, we do not envisage a situation,
except death, in which a participant would need to be
withdrawn. Arrangements will be made by the trial team
for further assessment and management as agreed with
the relevant authorities, GP and participant.
The investigator will provide the trial team with a 1-
month follow-up report on all SAEs. Further monthly
reports should be provided in the absence of resolution.
These reports will be communicated to the Programme
Steering Committee, REC, and to the local R&D office.




The Chief Investigator has obtained approval from a
recognised NRES Research Ethics Committee & Health
Research Authority (HRA) (Additional file 2). The study
will be conducted in accordance with the recommenda-
tions for physicians involved in research on human sub-
jects adopted by the 18th World Medical Assembly,
Helsinki 1964 (incl. later revisions) and any other rele-
vant ethical guidance.
Protocol amendments
After obtaining a favourable ethical opinion and HRA
approval, any subsequent changes to the study conduct,
design or management will be notified to the original ap-
proving REC & HRA and any other relevant regulatory




Written information about the RCT and an invite email/
letter will be emailed or posted to potential participants
who have previously completed the IBD-BOOST Survey
(stage 2 of the research programme) and have consented
to further approaches to participate in research. Partici-
pants will be able to participate by providing consent on-
line on the study website or by returning a completed
consent form by post (Additional file 4). There will be
two reminders by text or email after 1 and 3 weeks for
non-responders.
All participants are free to withdraw from the study at
any time without giving reasons and without prejudicing
further treatment. In line with GDPR guidelines, partici-
pant rights to access, change or remove their informa-
tion will be limited. If a participant chooses to withdraw
from the study, we will keep the information that we
have already obtained. To safeguard participant rights,
we will use the minimum personally identifiable infor-
mation possible at all stages of the study. Study partici-
pants will notify the chief investigator and/or lead
research team based at KCL if they wish to withdraw,
using the contact details provided in patient information
leaflets for the study and on the website.
Confidentiality of participants
The Chief Investigator will preserve the confidentiality
of participants taking part in the study and will work in
accordance with the Caldicott Principles, Data
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Protection Act 2018, NHS Code of Confidentiality and
any relevant NHS Trust organisational policies or other
applicable Data Protection legislation. Data collected
may be used to support other research in the future and
may be shared anonymously with other researchers as
stated in the PIL and consent form subject to the neces-
sary regulatory approvals being in place.
Access to data
Trial investigators and the relevant members of the
study team (i.e. trial statistician, health economist and
those involved in process evaluation) at KCL and the
PCTU will have access to the final trial data set. The
sponsor will archive trial data including identifiable in-
formation for 10 years after the trial has finished.
Ancillary and post-trial care
The study is sponsored by the LNWUH NHS Trust; the
NHS Litigation Authority (NHSLA) Indemnity scheme
will cover the study.
Dissemination
For authorship eligibility, we will follow the recognised
guidelines for authorship (https://www.bmj.com/about-
bmj/resources-authors/article-submission/authorship-
contributorship).
It is not intended to use professional writers.
Participants can request copies of a lay summary of
the final report of the outcome of the study by indicating
that they want this and giving permission to store con-
tact details for this purpose on the consent form.
To health professionals who could develop services, and
the academic community
We will submit results for publication in multidisciplin-
ary academic journals (such as Inflammatory Bowel Dis-
eases and Journal of Crohn’s & Colitis) to disseminate to
professional audiences. We will submit to key IBD con-
ferences, including the UK British Society of Gastro-
enterology, the European Crohn’s & Colitis Organisation
and the USA Digestive Diseases Week.
Anticipated professional publications include:
 Primary and secondary outcomes paper
 Health Economics evaluation paper
 Mediators and moderators of outcome
 Process Evaluation paper
 Study Protocol (current paper)
We will also work with our patient and public volun-
teers, training those who are willing to present results at
local and regional Crohn’s & Colitis UK meetings. We
will alongside patients construct a user-friendly lay sum-
mary for the CCUK newsletter and website. We will
prepare a more detailed summary of results in lay lan-
guage for participants and people with IBD who request
this and adapt the charity information sheet on bowel
control, fatigue and pain accordingly. We will discuss
dissemination via their newsletter with the European
Federation of Crohn’s & Colitis (patient) Associations.
The study team are members of all these groups.
Patient and public involvement (PPI)
People with IBD have been extensively involved in devel-
oping this research. In particular, PPI has informed or
will inform:
 Identification of the research questions for the
programme
 Development of the intervention
 Design of the research (including development of
patient-facing materials)
 Management of the research
 Undertaking the research
 Analysis of results
 Dissemination of findings
Discussion
This will be the first large-scale RCT of symptom manage-
ment in IBD and the first to attempt to address multiple
symptoms in the same intervention. The intervention has
been rigorously developed using a theoretically based logic
model. If the online self-management programme for
those with IBD-related symptoms of fatigue, pain and ur-
gency is shown to improve patients’ quality of life, this
trial will enable clinicians and patients to make informed
management decisions. The intervention has been de-
signed to be easily scalable and implemented. This is to
our knowledge the first trial focused on multiple symp-
toms that have been prioritised by both people with IBD
and health professionals. If the intervention improves
Quality of Life, it has potential to be adapted to the same
symptoms of fatigue, pain and urgency in other conditions
or for additional symptoms of IBD to be added.
Trial status
Protocol version 3.0 (16.06.2020). Ethics approval has
been obtained and site set-up is in progress. We com-
menced recruitment in January 2020 and anticipate
completing recruitment of 680 participants in July 2022.
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